Cubist Pharmaceuticals Inc.
) received some encouraging news when the US Food and Drug
Administration (FDA) designated its antibiotic candidate CXA-201
(ceftolozane/tazobactam) as a qualified infectious disease
product (QIDP), under the Generating Antibiotic Incentives Now
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
CUBIST PHARM (CBST): Free Stock Analysis
MEDICINES CO (MDCO): Free Stock Analysis
OPTIMER PHARMAC (OPTR): Free Stock Analysis
To read this article on Zacks.com click here.
The designation was granted for the hospital-acquired bacterial
pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP)
and complicated urinary tract infections (cUTI) indications.
CXA-201 is undergoing phase III studies for the cUTI indication.
The company intends to evaluate the candidate in a phase III
study for treating patients suffering from VABP. The study is
expected to commence in mid-2013.
With the FDA granting CXA-201 QIDP status for the above
indications, the antibiotic qualifies for multiple benefits
including a 5-year extension of Hatch-Waxman exclusivity (on
approval) and priority review.
We note that the GAIN act was signed into law by the US president
in Jul 2012 as part of the FDA Safety and Innovation Act
(FDASIA). The signing of the GAIN Act should benefit companies
pursuing the development of novel antibiotics. Apart from Cubist
Pharma, companies such as
The Medicines Company
) stand to benefit from the signing of the act.
Cubist Pharma received further good news when the FDA granted
fast track designation to CXA-201 for the complicated
intra-abdominal infections (cIAI) indication. CXA-201 is
undergoing phase III studies for the cIAI indication.
Furthermore, CB-315 (another pipeline candidate at Cubist Pharma)
was also granted fast track status. CB-315 is undergoing phase
III studies for treating patients suffering from clostridium
difficile-associated diarrhea (CDAD). We note that CXA-201 and
CB-315 were granted QIDP status for the cIAI and CDAD
indications, respectively, late last year.
Cubist Pharma, a biopharmaceutical company, carries a Zacks Rank
#3 (Hold). Biopharma stocks, which are presently well placed,
) carrying a Zacks Rank #2.